(R)-3-(dibenzylamino)-2-fluoropropanoic acid | 137650-05-6

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: (R)-3-(dibenzylamino)-2-fluoropropanoic acid
• 英文别名: (2R)-3-(dibenzylamino)-2-fluoropropanoic acid
• CAS: 137650-05-6
• 化学式: C₁₇H₁₈FNO₂
• 分子量: 287.334
• InChiKey: AOTXCKTZBUSXFK-MRXNPFEDSA-N

物化性质

• 沸点：
  417.4±40.0 °C(Predicted)
• 密度：
  1.196±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.9
• 重原子数：
  21
• 可旋转键数：
  7
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.24
• 拓扑面积：
  40.5
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  (R)-3-(dibenzylamino)-2-fluoropropanoic acid 在 1-羟基苯并三唑 、 盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺 、 N,N-二异丙基乙胺 作用下， 以 四氢呋喃 、 乙醚 、 N,N-二甲基甲酰胺 为溶剂， 反应 1.0h， 生成 (R)-4-(dibenzylamino)-3-fluorobutan-2-one
  参考文献：
  名称：

  [EN] HETEROARYL SUBSTITUTED PYRIDYL COMPOUNDS USEFUL AS KINASE MODULATORS
  [FR] COMPOSÉS PYRIDYLE À SUBSTITUTION HÉTÉROARYLE UTILES EN TANT QUE MODULATEURS DE KINASE

  摘要：

  具有以下式(I)或其立体异构体或药用可接受盐的化合物，在该式中R2是单环杂芳基，R1、R3、R4、R5和R6如本文所定义，可用作激酶调节剂，包括IRAK-4抑制剂。

  公开号：

  WO2014074675A1
• 作为产物：
  描述：

  phenylmethyl 3--2(R)-fluoropropanoate 在 lithium hydroxide 作用下， 以 四氢呋喃 为溶剂， 反应 16.0h， 以93%的产率得到(R)-3-(dibenzylamino)-2-fluoropropanoic acid
  参考文献：
  名称：

  Preparation and opioid activity of analogs of the analgesic dipeptide 2,6-dimethyl-L-tyrosyl-N-(3-phenylpropyl)-D-alaninamide

  摘要：

  A number of analogues of the recently disclosed analgesic dipeptide 2,6-dimethyl-L-tyrosyl-D-alanine-phenylpropylamide (SC-39566,2) were prepared. These analogues contained oxymethylene, aminomethylene, ketomethylene, bismethylene, and trans double bond (including vinyl fluoride) isosteric replacements for the amide bond between the D-alanine and phenylpropylamine units in 2. These compounds were tested in opioid binding assays and in the mouse writhing assay for analgesic activity. Though not as potent as 2, the oxymethylene, and trans double bond isosteres showed analgesic activity. The aminomethylene analogues also showed binding activity in subnanomolar concentrations at the mu-receptor. The amide bond between 2,6-dimethyl-L-tyrosine and D-alanine units seems to be critical for opioid activity.

  DOI：

  10.1021/jm00080a005

文献信息

• HETEROARYL SUBSTITUTED NICOTINAMIDE COMPOUNDS
  申请人：BRISTOL-MYERS SQUIBB COMPANY

  公开号：US20150191464A1

  公开（公告）日：2015-07-09

  Disclosed are compounds of Formula (I) or salts thereof, wherein: HET is a heteroaryl selected from pyrazolyl, indolyl, pyrrolo[2,3-b]pyridinyl, pyrrolo[2,3-d]pyrimidinyl, pyrazolo[3,4-b]pyridinyl, pyrazolo[3,4-d]pyrimidinyl, 2,3-dihydro-1H-pyrrolo[2,3-b]pyridinyl, imidazo[4,5-b]pyridinyl, and purinyl, wherein said heteroaryl is substituted with R a and R b ; and R 1 and R 2 are define herein. Also disclosed are methods of using such compounds as modulators of IRAK4, and pharmaceutical compositions comprising such compounds. These compounds are useful in treating, preventing, or slowing inflammatory and autoimmune diseases.

  公开的是Formula (I)的化合物或其盐，其中：HET是从吡唑基、吲哚基、吡咯并[2,3-b]吡啶基、吡咯并[2,3-d]嘧啶基、吡唑并[3,4-b]吡啶基、吡唑并[3,4-d]嘧啶基、2,3-二氢-1H-吡咯并[2,3-b]吡啶基、咪唑并[4,5-b]吡啶基和嘌呤基中选择的杂环芳基，其中所述杂环芳基被R a 和R b 取代；以及R 1 和R 2 在此处定义。还公开了使用这些化合物作为IRAK4调节剂的方法，以及包含这些化合物的药物组合物。这些化合物在治疗、预防或减缓炎症性和自身免疫性疾病方面是有用的。
• FERROPORTIN INHIBITORS AND METHODS OF USE
  申请人：GLOBAL BLOOD THERAPEUTICS, INC.

  公开号：US20200190045A1

  公开（公告）日：2020-06-18

  The subject matter described herein is directed to Ferroportin inhibitor compounds of Formula I and pharmaceutical salts thereof, methods of preparing the compounds, pharmaceutical compositions comprising the compounds and methods of administering the compounds for prophylaxis and/or treatment of diseases caused by a lack of hepcidin or iron metabolism disorders, particularly iron overload states, such as thalassemia, sickle cell disease and hemochromatosis.

  本文描述的主题是关于Formula I的Ferroportin抑制剂化合物及其制药盐，制备这些化合物的方法，包含这些化合物的制药组合物以及为预防和/或治疗由于缺乏hepcidin或铁代谢紊乱引起的疾病而给予这些化合物的方法，尤其是铁过载状态，如地中海贫血、镰状细胞病和血色沉着症。
• [EN] BICYCLIC HETEROCYCLE SUBSTITUTED PYRIDYL COMPOUNDS USEFUL AS KINASE MODULATORS<br/>[FR] COMPOSÉS PYRIDYLES À SUBSTITUTION PAR HÉTÉROCYCLE BICYCLIQUE UTILES EN TANT QUE MODULATEURS DE KINASE
  申请人：BRISTOL MYERS SQUIBB CO

  公开号：WO2014074657A1

  公开（公告）日：2014-05-15

  Compounds having the following formula (I) or a stereoisomer or a pharmaceutically-acceptable salt thereof, wherein R2 is a bicyclic heterocycle, and R1, R3, R4, R5 and R6 are as defined herein, that are useful as kinase modulators, including IRAK-4 modulation.

  具有以下式(I)的化合物或其立体异构体或药用盐，其中R2是双环杂环，R1、R3、R4、R5和R6如本文所定义，这些化合物可用作激酶调节剂，包括IRAK-4调节。
• Crystallization-Induced Dynamic Resolution of Fox Chiral Auxiliary and Application to the Diastereoselective Electrophilic Fluorination of Amide Enolates
  作者：Hodney Lubin、Christophe Dupuis、Julien Pytkowicz、Thierry Brigaud

  DOI：10.1021/jo400210j

  日期：2013.4.5

  efficient crystallization-induced dynamic resolution (CIDR) of trans-Fox (fluorinated oxazolidine) chiral auxiliary is reported. This chiral auxiliary was used for highly diastereoselective (>98% de) electrophilic fluorination of amide enolates. After removal of the chiral auxiliary, highly valuable enantiopure α-fluorocarboxylic acids and β-fluoroalcohols are obtained.

  的高效率的结晶诱导的动态分辨率（CIDR）反式-福克斯（氟化恶唑烷）手性辅助剂的报道。该手性助剂用于酰胺烯酸酯的高度非对映选择性（> 98％de）亲电氟化。除去手性助剂后，获得了高度有价值的对映纯α-氟代羧酸和β-氟代醇。
• New aminopropylphosphinic acids
  申请人：Elebring Thomas

  公开号：US20050137414A1

  公开（公告）日：2005-06-23

  Novel compounds of formula I, with the exception of i) the racemate of (3-amino-2-hydroxypropyl)phosphinic acid; and ii) (2R/S, 3R)-(3-amino-2-hydroxybutyl)phosphinic acid, having affinity to one or more GABA B receptors, their pharmaceutically acceptable salts, solvates and stereoisomers, as well as processes for their preparation, pharmaceutical compositions containing said therapeutically active compounds and the use of said active compounds in therapy.

  公式I的新化合物，除了i) (3-氨基-2-羟基丙基)磷酸缩氨酸的外消旋体;和ii) (2R / S，3R) - (3-氨基-2-羟基丁基)磷酸缩氨酸，具有与一个或多个GABAB受体亲和力，它们的药学上可接受的盐，溶剂和立体异构体，以及它们的制备过程，含有所述治疗活性化合物的药物组合物以及在治疗中使用所述活性化合物的用途。